Abstract
Real-world quality of life (QOL) for patients (pts) with metastatic renal cell carcinoma (mRCC) treated with systemic therapy (ST) in the prospective observational ODYSSEY study
Journal of clinical oncology, Vol.43(16_suppl), pp.4558-4558
06/2025
DOI: 10.1200/JCO.2025.43.16_suppl.4558
Abstract
4558
Background: In the past 7 years, 4 immuno-oncology (IO) based combinations have been approved for mRCC. However, QOL data on these combinations are limited to trials in which collection and reporting was not standardized, which further limits cross trial comparisons. Real-world QOL data with multiple treatment regimens are needed to understand how these regimens are tolerated in practice. Methods: ODYSSEY is a multi-site, prospective observational study of 500 US pts with mRCC. Pts must have mRCC (any histology), no prior ST, and follow up at a PCORnet study site. Exclusion criteria include treatment for cancer except mRCC. The primary objective is to determine patterns of change in QOL and symptom burden of pts with mRCC. Minimally important differences (MID) are 3 points for FKSI-19 total score, 1 point for the FKSI-Disease Related Symptoms (DRS) subscale and 7 points for FACT-G. Results: As of 1/6/25, 392 pts were enrolled of whom 299 were managed with ST. Of pts on ST, 114 were treated with IO-IO, 108 with IO-TKI, 33 with IO alone, 27 with Other, and 18 with TKI alone. Median follow up for all pts is 8.8 months (IQR 2.9, 16.2). IO-IO pts are median age 64 yrs, 81% male, 84% white, 56% prior nephrectomy, 84% clear cell; IO-TKI pts median age 66 yrs, 76% male, 92% white, 43% prior nephrectomy, 66% clear cell; IMDC risk profiles are similar. IO-IO pts are more likely to be KPS 100; whereas, IO-TKI pts have a higher median number of metastatic sites and are more likely to have bone or liver metastasis. With median follow-up of 6.0 (IQR 1.8, 14.9) and 8.8 months (4.5, 17.8) in the IO-IO and IO-TKI cohorts, 17 (15%) and 21 (19%) pts had died with a median time to death of 5.4 (2.5, 6.4) and 5.7 months (4.4, 12.8), respectively. 20 (18%) and 16 (15%) pts on IO-IO and IO-TKI had discontinued therapy at a median of 3.0 (IQR 2.0, 4.0) and 6.4 months (2.4, 13.0), respectively. Rates of discontinuation for disease progression and toxicity are similar. Baseline PROs for pts on ST are shown in the Table (higher score indicates better QOL), with RCT data for reference (NA, not assessed). Conclusions: In our prospective multi-center ODYSSEY study, we demonstrate that real world pts treated with contemporary ST have worse baseline QOL than those enrolled on pivotal RCTs. One-third of IO-IO and IO-TKI pts died or discontinued therapy within 6 months of initiation. Our data on real world vs RCT differences in baseline QOL may partially explain the limitations of current IO combination regimens in practice and support development of alternative treatment approaches. Instrument, Mean (SD) ODYSSEYIO-IO(N=114) CheckMate214(N=425) ODYSSEYIO-TKI(N=108) KEYNOTE426(N=402) CheckMate9ER(N=323) CLEAR(N=351) FKSI-19 total 56.0 (12.5) 60.1 (9.8) 53.8 (11.8) NA 58.7 (10.6) NA FKSI-DRS 27.5 (6.3) 30.7 (4.5) 27.0 (5.8) 32 (4.2) 30.2 (5.2) 31.3 (4.4) FACT-G 82.4 (16.7) 82.6 (15.0) 78.5 (16.0) NA NA NA
Details
- Title: Subtitle
- Real-world quality of life (QOL) for patients (pts) with metastatic renal cell carcinoma (mRCC) treated with systemic therapy (ST) in the prospective observational ODYSSEY study
- Creators
- Benjamin L. Maughan - University of UtahJesse D. Troy - Duke UniversityYousef Zakharia - Mayo Clinic HospitalElizabeth Marie Wulff-Burchfield - University of Kansas Medical CenterNrupen Anjan Bhavsar - Duke University Health SystemYasser Ged - Johns Hopkins MedicineAjjai Shivaram Alva - University of Michigan–Ann ArborPriyanka V. Chablani - University of Pittsburgh Medical CenterBrian Addis Costello - Mayo ClinicDeepak Kilari - Medical College of WisconsinSorab Gupta - Einstein Healthcare NetworkMelyssa Bratton - Ochsner Health SystemMuhammad Furqan - University of IowaTracy L. Rose - University of North Carolina at Chapel HillSarah Jabusch - Duke Cancer InstituteKimberly T. Ward - Duke Cancer InstituteCourtney Page - Duke Cancer InstituteDaniel J. George - Duke Cancer InstituteTian Zhang - The University of Texas Southwestern Medical CenterMichael Roger Harrison - Duke Cancer Institute
- Resource Type
- Abstract
- Publication Details
- Journal of clinical oncology, Vol.43(16_suppl), pp.4558-4558
- DOI
- 10.1200/JCO.2025.43.16_suppl.4558
- ISSN
- 0732-183X
- eISSN
- 1527-7755
- Language
- English
- Date published
- 06/2025
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984843244402771
Metrics
1 Record Views